EA202191373A1 - Фармацевтическая композиция и способ ее получения - Google Patents

Фармацевтическая композиция и способ ее получения

Info

Publication number
EA202191373A1
EA202191373A1 EA202191373A EA202191373A EA202191373A1 EA 202191373 A1 EA202191373 A1 EA 202191373A1 EA 202191373 A EA202191373 A EA 202191373A EA 202191373 A EA202191373 A EA 202191373A EA 202191373 A1 EA202191373 A1 EA 202191373A1
Authority
EA
Eurasian Patent Office
Prior art keywords
pharmaceutical composition
obtaining
amorphous
lamivudine
ritonavir
Prior art date
Application number
EA202191373A
Other languages
English (en)
Inventor
Ацуси Кано
Со Тойонага
Original Assignee
Фуджифилм Корпорэйшн
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Фуджифилм Корпорэйшн filed Critical Фуджифилм Корпорэйшн
Publication of EA202191373A1 publication Critical patent/EA202191373A1/ru

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/427—Thiazoles not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/38—Cellulose; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Inorganic Chemistry (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Предложены фармацевтическая композиция, содержащая аморфную твердую дисперсию, содержащую аморфные лопинавир и ритонавир и полимер на основе целлюлозы, и ламивудин; и способ получения фармацевтической композиции.
EA202191373A 2018-12-14 2019-12-13 Фармацевтическая композиция и способ ее получения EA202191373A1 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2018234691 2018-12-14
PCT/JP2019/049013 WO2020122241A1 (ja) 2018-12-14 2019-12-13 医薬組成物及びその製造方法

Publications (1)

Publication Number Publication Date
EA202191373A1 true EA202191373A1 (ru) 2021-12-27

Family

ID=71076924

Family Applications (1)

Application Number Title Priority Date Filing Date
EA202191373A EA202191373A1 (ru) 2018-12-14 2019-12-13 Фармацевтическая композиция и способ ее получения

Country Status (2)

Country Link
EA (1) EA202191373A1 (ru)
WO (1) WO2020122241A1 (ru)

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2014130553A2 (en) * 2013-02-20 2014-08-28 Abbvie Inc. Tablet dosage forms

Also Published As

Publication number Publication date
WO2020122241A1 (ja) 2020-06-18

Similar Documents

Publication Publication Date Title
UY37278A (es) Anticuerpos anti-b7-h3 y conjugados de fármaco y anticuerpos
WO2018128662A3 (en) Large scale optical phased array
CO2018005525A2 (es) Formulación farmacéutica acuosa del anticuerpo anti-pd-l1 avelumab
BR112018075644A2 (pt) anticorpos anti-cd98 e conjugados de anticorpo e fármaco
BR112016020112A2 (pt) anticorpos multiespecíficos, método para a preparação de um anticorpo multiespecífico, ácido nucleico, vetor de expressão e composição farmacêutica
EA201891087A1 (ru) Ингибиторы ret
EA201792590A1 (ru) КОНЪЮГАТ АНТИТЕЛА ПРОТИВ ErbB2 И ЛЕКАРСТВЕННОГО СРЕДСТВА И ЕГО КОМПОЗИЦИЯ, СПОСОБ ЕГО ПОЛУЧЕНИЯ И ЕГО ПРИМЕНЕНИЕ
TWD178161S (zh) 物聯網智慧裝置
BR112015001768A2 (pt) método e dispositivo para processamento de modo infantil
CL2017001457A1 (es) Régimen de dosificación para un agonista selectivo del receptor s1p1.
BR112018075630A2 (pt) anticorpos anti-cd98 e conjugados de fármaco de anticorpo
BR112016025056A2 (pt) uso de pelo menos um polipeptídeo, anticorpo biespecífico, anticorpo biespecífico isolado, anticorpo her3/her2 biespecífico, célula hospedeira, método de produção do anticorpo biespecífico her3/her2, imunoconjugado e formulação farmacêutica
BR112017002060A2 (pt) novo uso
BR112017019004A2 (pt) metadados de campo de luz
EA201690099A1 (ru) Устойчивая жидкая композиция, содержащая amg-416 (велкальцетид)
MX2017009759A (es) Formulacion de anticuerpo del anti-factor de crecimiento endotelial vascular (vegf) acuosa estable.
BR112018014355A2 (pt) processos para a preparação de f-benzoxazinorifamicina i e para a preparação de 2-amino-5-fluorobenzeno-1,3-diol iii
EA202091400A1 (ru) Производные пиррола в качестве ингибиторов асс
EA201790155A1 (ru) Перегрузочное устройство для стеклянной подложки
BR112017025427A2 (pt) composição farmacêutica oral
BR112016017609A2 (pt) Composição, e, processo
BR112016024457A2 (pt) anticorpo isolado, imunoconjugado, uso do anticorpo, formulação farmacêutica, ácido nucleico isolado, célula hospedeira e método de produção de um anticorpo
EA201792312A1 (ru) Конструкции на основе калихеамицина и способы их применения
BR112017028242A2 (pt) sistema de comunicação portátil dinâmico
EA202191373A1 (ru) Фармацевтическая композиция и способ ее получения